Verrica Pharmaceuticals Inc Stock News

Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025

Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Chris Calabrese - MD, LifeSci Advisors Ted White - President & CEO Joe Bonacc

Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.13 per share a year ago.

– Reports YCANTH® revenue of $3.2M for first quarter of 2024  – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – �

WEST CHESTER, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin

WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin

Verrica Pharmaceuticals (VRCA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in th

WEST CHESTER, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring

NCE status provides a minimum of five years of regulatory exclusivity The Company's U.S. patents and pending patent applications related to YCANTH™ are projected to expire between 2034 and 2041, exc

Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript

– Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 – – Over 200 million lives now covered on commercial insurance and managed Medicaid plans – – Conference

WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for ski

WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for ski

Lawsuit alleges false and misleading advertising and promotion of unapproved cantharidin-containing drugs by Dormer Laboratories in violation of federal and state law

WEST CHESTER, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for ski